Vanda Pharmaceuticals (VNDA) Total Liabilities (2010 - 2026)

Vanda Pharmaceuticals has reported Total Liabilities for 17 years, with the latest figure at $152.8 million in Q1 2026.

• Quarterly Total Liabilities rose 26.75% year-over-year to $152.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $152.8 million (up 26.75% YoY) and the FY2025 annual result came in at $161.8 million, up 37.48% from the prior year.
• Total Liabilities slipped to $152.8 million in Q1 2026 per VNDA's latest filing, from $161.8 million in the prior quarter.
• Over five years, Total Liabilities peaked at $161.8 million in Q4 2025 and troughed at $98.5 million in Q3 2023.
• A 5-year average of $116.2 million and a median of $108.7 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Liabilities slipped 7.19% in 2023, then jumped 37.48% in 2025.
• Over 5 years, Total Liabilities stood at $107.0 million in 2022, then retreated by 3.29% to $103.5 million in 2023, then grew by 13.65% to $117.7 million in 2024, then soared by 37.48% to $161.8 million in 2025, then slipped by 5.56% to $152.8 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $152.8 million, $161.8 million, and $135.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.